Menu
Search
|

Menu

Close
X

Aerie Pharmaceuticals Inc AERI.OQ (NASDAQ Stock Exchange Global Market)

73.80 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 73.80
Open --
Volume --
3m Avg Volume 116,374
Today’s High --
Today’s Low --
52 Week High 74.55
52 Week Low 47.05
Shares Outstanding (mil) 39.50
Market Capitalization (mil) 2,914.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.82 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.054
FY17
-4.078
FY16
-3.399
FY15
-2.883
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
--
8.04
Price to Book (MRQ)
vs sector
12.34
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
52.45
17.43
LT Debt to Equity (MRQ)
vs sector
52.45
13.25
Return on Investment (TTM)
vs sector
-55.39
13.23
Return on Equity (TTM)
vs sector
-99.89
15.27

EXECUTIVE LEADERSHIP

Vicente Anido
Chairman of the Board, Chief Executive Officer, Since 2013
Salary: $549,016.00
Bonus: $329,410.00
Thomas Mitro
President, Chief Operating Officer, Since 2013
Salary: $403,150.00
Bonus: $191,497.00
Casey Kopczynski
Co-Founder, Chief Scientific Officer, Since 2005
Salary: --
Bonus: --
Richard Rubino
Chief Financial Officer, Secretary, Since 2015
Salary: $387,300.00
Bonus: $180,000.00
Deanne Melloy
Vice President - Marketing, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7020 Kit Creek Rd Ste 270
RESEARCH TRIANGLE PARK   NC   27709-0014

Phone: +1919.3139650

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

SPONSORED STORIES